Compare RCAT & GLUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RCAT | GLUE |
|---|---|---|
| Founded | 2002 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Wholesale Distributors | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.2B |
| IPO Year | 2017 | 2021 |
| Metric | RCAT | GLUE |
|---|---|---|
| Price | $8.26 | $14.31 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $20.00 | ★ $32.00 |
| AVG Volume (30 Days) | ★ 8.7M | 1.2M |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | $17,836,382.00 | ★ $123,672,000.00 |
| Revenue This Year | $271.60 | N/A |
| Revenue Next Year | $41.21 | $2.45 |
| P/E Ratio | ★ N/A | $72.42 |
| Revenue Growth | ★ 79.95 | 63.54 |
| 52 Week Low | $5.77 | $4.79 |
| 52 Week High | $18.78 | $25.77 |
| Indicator | RCAT | GLUE |
|---|---|---|
| Relative Strength Index (RSI) | 40.90 | 36.40 |
| Support Level | $7.16 | N/A |
| Resistance Level | $8.85 | $16.66 |
| Average True Range (ATR) | 0.63 | 0.72 |
| MACD | -0.17 | 0.11 |
| Stochastic Oscillator | 1.69 | 34.19 |
Red Cat Holdings Inc is a drone technology company integrating robotic hardware and software for military, government, and commercial operations. Its suite of solutions includes the Arachnid family of ISR and precision strike drones, which includes the Black Widow, a small unmanned ISR system; and WEB (Warfighter Electronic Bridge) GCS, designed to command and control an entire drone family of systems for military operations. Its other offerings include Edge 130 Blue drone systems, Trichon, a fixed-wing VTOL for extended endurance and range, and FANG FPV drones optimized for military operations with precision strike capabilities. The firm's Division includes Teal, FlightWave, and Blue Ops.
Monte Rosa Therapeutics Inc is a clinical-stage biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. The company has three programs in clinical development: MRT-6160, a VAV1-directed MGD for immune-mediated diseases; MRT-8102, a NEK7-directed MGD for inflammatory diseases driven by IL-6, and the NLRP3 inflammasome; and MRT-2359, a GSPT1-directed MGD for metastatic castration resistant prostate cancer (mCRPC).